Composition:
 Each modified-release film-coated tablet contains Mirabegron 50 mg and Solifenacin succinate 5 mg.
 

Therapeutic indications: 
Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.